10 terminated, 7 active not recruiting, 6 recruiting, 5 completed. 14 Phase 2, 13 Phase 1, 2 Early Phase 1, 1 Not applicable.
Follow Pathologic Stage IV Cutaneous Melanoma AJCC v8: new trials by email Literature Review of Pathologic Stage IV Cutaneous Melanoma AJCC v8 trials Research Report on Pathologic Stage IV Cutaneous Melanoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain Natural Killer Cell Therapy, Temozolomide - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain | Phase 1 / Phase 2 | Recruiting | Kari Kendra | 24 | 2023-03-01 | 2026-06-11 |
| Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases Ipilimumab, Nivolumab, Pembrolizumab - Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 1 | Terminated | Emory University | 1 | 2022-10-13 | 2026-04-23 |
| Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases Binimetinib, Encorafenib, Questionnaire Administration - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 35 | 2021-12-27 | 2026-04-16 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| 7T MRI Scan for the Early Detection of Melanoma Brain Metastases Magnetic Resonance Imaging using 7 Tesla MRI - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain | Not applicable | Terminated | University of Southern California | 2 | 2021-06-25 | 2025-08-12 |
| Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration - Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 5 | 2021-06-01 | 2026-10-06 |
| Bone Loss in Melanoma Survivors Receiving Immunotherapy Biospecimen Collection, Dual X-ray Absorptiometry - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Terminated | M.D. Anderson Cancer Center | 12 | 2021-05-10 | 2025-08-17 | |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-14 | 2026-04-30 |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer Best Practice, Biospecimen Collection, Endoscopic Procedure - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 800 | 2021-02-21 | 2026-07-15 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Early Phase 1 | Completed | University of Southern California | 10 | 2021-02-15 | 2024-05-24 |
| Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Ipilimumab, Nivolumab, Patient Observation - Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 150 | 2021-02-09 | 2026-09-15 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2021-01-15 | 2026-03-18 |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases Binimetinib, Encorafenib, Ipilimumab - Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 112 | 2021-01-06 | 2026-09-15 |
| Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma Binimetinib, Nivolumab, Questionnaire Administration - Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8 | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 3 | 2020-12-03 | 2024-12-04 |
| Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy Dietary Intervention, Quality-of-Life Assessment, Questionnaire Administration - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 50 | 2020-06-24 | 2026-01-30 |
| The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis - Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Completed | Ohio State University Comprehensive Cancer Center | 88 | 2020-02-10 | 2023-04-24 | |
| Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Ipilimumab, Nivolumab, Prednisone - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2019-11-08 | 2026-10-14 |
| CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma FACT Complex-targeting Curaxin CBL0137 - Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity | Phase 1 | Terminated | Roswell Park Cancer Institute | 7 | 2019-07-01 | 2024-03-27 |
Showing 20 of 28. Sign in to see all of them.
Melanoma (20) · Brain Neoplasms (10) · Lung Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (4) · Neoplasm Metastasis (4) · Ovarian Neoplasms (4) · Uveal Melanoma (4) · Carcinoma, Renal Cell (3) · Breast Neoplasms (2) · Fallopian Tube Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Urinary Bladder Neoplasms (2) · Urogenital Neoplasms (2) · Adenocarcinoma of Lung (1)
Neoplasms (23) · Neoplasms by Site (23) · Neoplasms by Histologic Type (21) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Nerve Tissue (20) · Neuroectodermal Tumors (20) · Nevi and Melanomas (20) · Skin Diseases (20) · Skin Neoplasms (20) · Skin and Connective Tissue Diseases (20) · Neuroendocrine Tumors (19) · Brain Diseases (10) · Central Nervous System Diseases (10) · Central Nervous System Neoplasms (10) · Nervous System Diseases (10)
CTLA-4 Antigen (8) · Ipilimumab (8) · Nivolumab (8) · Disulfides (5) · Immunoglobulin G (5) · pembrolizumab (5) · Cyclophosphamide (3) · binimetinib (3) · Bevacizumab (2) · Magnetic Resonance Spectroscopy (2) · Paclitaxel (2) · Prednisone (2) · Radiosurgery (2) · Specimen Handling (2) · Taxes (2)
M.D. Anderson Cancer Center (13) · ECOG-ACRIN Cancer Research Group (2) · Mayo Clinic (2) · Roswell Park Cancer Institute (2) · University of Southern California (2) · Anusha Kalbasi (1) · Emory University (1) · Jonsson Comprehensive Cancer Center (1) · Kari Kendra (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1)
United States (28)
Isabella C Glitza (2) · Allison Betof Warner, MD, PhD (1) · Antoni Ribas, MD, PhD (1) · Aung Naing, MD (1) · Daniel Spakowicz, PhD (1) · David S Hong (1) · Erez Baruch, MD,PHD (1) · Evan J Lipson (1) · Geoffrey T Gibney (1) · Hossein Jadvar, MD (1) · Hussein A Tawbi (1) · Hussein A Tawbi, MD (1) · Jewel Samadder, M.D. (1) · Jing Li (1) · Joseph Skitzki (1)
PMID 28428884, PMID 32503950, PMID 33909232, PMID 34562230, PMID 34965890, PMID 35537412, PMID 36821617, PMID 37129197, PMID 37328287, PMID 38252910, PMID 39633321, PMID 39816915, PMID 39945382, PMID 40439484, PMID 40580957
P30CA014089 (2), U10CA180820 (2), P30CA016056 (1), P30CA016672 (1), P30CA138292 (1), R01CA164333 (1), U10CA180888 (1), UM1CA186691 (1)